WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2013050419) PHARMACEUTICAL COMPOSITIONS COMPRISING 40 - O - ( 2 - HYDROXY) ETHYL - RAPAMYCIN
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2013/050419    International Application No.:    PCT/EP2012/069541
Publication Date: 11.04.2013 International Filing Date: 03.10.2012
Chapter 2 Demand Filed:    31.07.2013    
IPC:
A61K 9/20 (2006.01), A61K 9/50 (2006.01), A61K 31/436 (2006.01)
Applicants: NOVARTIS AG [CH/CH]; Lichtstrasse 35 CH-4056 Basel (CH) (For All Designated States Except US).
DIEDERICH, Anke [DE/CH]; (CH) (US only).
LIECHTI, Kurt [CH/CH]; (CH) (US only).
KUEHL, Peter [DE/CH]; (CH) (US only).
CHEUNG, Wing [US/US]; (US) (US only)
Inventors: DIEDERICH, Anke; (CH).
LIECHTI, Kurt; (CH).
KUEHL, Peter; (CH).
CHEUNG, Wing; (US)
Agent: KRISTL, Jernej; Novartis Pharma AG Patent Department CH-4002 Basel (CH)
Priority Data:
61/544,026 06.10.2011 US
Title (EN) PHARMACEUTICAL COMPOSITIONS COMPRISING 40 - O - ( 2 - HYDROXY) ETHYL - RAPAMYCIN
(FR) COMPOSITIONS PHARMACEUTIQUES COMPRENANT 40 - O - ( 2 - HYDROXY) ÉTHYL - RAPAMYCINE
Abstract: front page image
(EN)The invention relates to extended release pharmaceutical formulations in form of multiparticulates comprising 40-O-(2-hydroxy)ethyl-rapamycin, to dosage forms which comprise said pharmaceutical formulations, to methods of preparing said pharmaceutical formulations and said dosage forms, to uses of said pharmaceutical formulations and said dosage for the manufacture of a medicament for the treatment or prevention of diseases or conditions responsive to inhibition of mTOR signaling pathway, such as for instance proliferative diseases or immunosuppression.
(FR)L'invention concerne des formulations pharmaceutiques à libération prolongée sous la forme de multiparticules comprenant 40-O-(2-hydroxy)éthyl-rapamycine, des formes pharmaceutiques qui comprennent lesdites formulations pharmaceutiques, des procédés de préparation desdites formulations pharmaceutiques et desdites formes pharmaceutiques, des utilisations de ces formulations pharmaceutiques et formes pharmaceutiques pour la fabrication d'un médicament destiné au traitement ou à la prévention de maladies ou d'états réagissant à l'inhibition de la voie de signalisation de mTOR, par exemple des maladies prolifératives ou l'immunosuppression.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)